SRC and non-small cell lung carcinoma: Through in vitro and in vivo experiments, the same study showed that treatment with the EGFR-TKI gefitinib, in combination with the SRC inhibitor saracatinib (AZD05300), had a synergistic antitumor effect on NSCLC cells [97].